Why cutting down is not a willpower problem
Most advice about drinking less assumes the difficulty is motivation: try harder, plan better, get an app.
The UK data points elsewhere. Around one adult in five in England drinks above the national guideline, the broad measure of alcohol-related hospital admissions is at its highest since records began in 2016/17, and four medicines already sit within NICE guidance.
What the UK guideline says
The UK Chief Medical Officers published their low risk drinking guidelines on 25 August 2016. To keep health risks from alcohol to a low level, it is safest not to drink more than 14 units a week on a regular basis. That figure applies equally to men and women.
A second instruction gets less attention: if you regularly drink as much as 14 units a week, spread it evenly over three or more days. One or two heavy drinking episodes a week increases your risk of death from long term illness and from accidents and injuries.
The risk of a range of health problems, including cancers of the mouth, throat and breast, rises the more you drink on a regular basis. No separate unit figure is given for a single occasion: limit the total, drink slowly, drink with food and alternate with water.
If you are pregnant or think you could become pregnant, the safest approach is not to drink alcohol at all.
How much people in England actually drink
Figures for 2024 from the Health Survey for England, collated by Alcohol Change UK, put mean weekly consumption among adults aged 16 and over at 12.8 units.
- 76 percent of adults say they drink alcohol
- 23 percent reported not drinking in the last 12 months, up from a stable 17 to 20 percent between 2011 and 2023
- 20 to 21 percent drink above the 14 unit guideline
- That splits as 27 percent of men and 15 percent of women
What the harm figures show
The Office for National Statistics registered 9,809 alcohol-specific deaths in the UK in 2024, a rate of 14.8 per 100,000. That is a 6.3 percent decrease on 2023, which was a record high of 10,473 deaths.
The male rate was 20.2 per 100,000 (6,480 deaths) and the female rate 9.7 (3,329 deaths). Rates differ across the UK: England 13.8 per 100,000, Wales 16.8, Scotland 20.9 and Northern Ireland 21.4, a record high for Northern Ireland.
Hospital data moves the other way. England recorded 339,916 alcohol-specific admissions in 2023/24 and 1,018,986 admissions under the broad measure that counts alcohol as a primary or secondary diagnosis, a rate of 1,625 per 100,000.
Not all liver disease is alcohol related. MASH is fatty liver disease that is not caused by alcohol.
The beliefs that make cutting down harder
Alcohol Change UK addresses three common ideas.
Alcohol helps me sleep. It does not. Alcohol may speed up falling asleep, but it reduces deep sleep, causes more waking during the night and relaxes the muscles in the airway.
Red wine is good for my heart. Alcohol Change UK states that no research has definitively shown a cause and effect link between drinking and better heart health, and that any purported benefit is outweighed by increased risk of high blood pressure, stroke and cancer. If heart risk is the worry, inherited factors such as lipoprotein(a) matter more.
Being fit cancels out the harm. It does not.
What tends to work when you cut down
Small habitual drinks are usually what builds a weekly unit total, which is why swapping and downsizing tends to work better than trying to stop outright in one step.
- Halves instead of pints
- Singles instead of doubles
- Lower ABV products in place of stronger ones
- Drinks spread evenly across three or more days
- Water alongside alcohol, and food with it, to slow the pace
What is available in the UK now
NICE guideline CG115, published on 23 February 2011 and last updated on 21 October 2014, sets out the medicines used for alcohol dependence.
Acamprosate is considered after successful withdrawal in moderate or severe dependence, or with psychological therapy in harmful or mildly dependent drinking. The usual dose is 1998 mg a day, taken as 666 mg three times daily, typically for up to six months.
Oral naltrexone is licensed in the UK for alcohol dependence. Starting dose 25 mg a day, maintenance 50 mg a day, typically for up to six months, alongside a psychological intervention.
Disulfiram is for people whose goal is abstinence where acamprosate or naltrexone are unsuitable. The usual dose is 200 mg a day. It causes flushing, nausea and palpitations if alcohol is consumed, and rarely serious arrhythmia or low blood pressure.
Nalmefene was recommended by NICE in 2014 with continuous psychosocial support, for reducing consumption in people with alcohol dependence at a high drinking risk level who do not need immediate detoxification. That level is more than 60 g of alcohol a day for men and 40 g for women, without physical withdrawal symptoms. It is an 18 mg tablet taken as needed.
Benzodiazepines manage acute withdrawal only. The NHS lists acamprosate, naltrexone and disulfiram alongside talking therapies such as CBT.
What research is looking at next
GLP-1 receptor agonists are the most active area of research into drinking, and the results need careful reading.
A 26 week randomised placebo-controlled trial of once-weekly exenatide plus CBT in treatment-seeking adults, published in JCI Insight on 10 October 2022, missed its primary outcome: no significant difference against placebo in heavy drinking days. An exploratory subgroup with a BMI above 30 did show a reduction.
A nine week phase 2 trial of low-dose semaglutide in 48 non-treatment-seeking adults, published in JAMA Psychiatry on 12 February 2025, reduced weekly craving and the amount consumed in a laboratory drinking session. It did not affect average drinks per day or the number of drinking days.
In The Lancet on 30 April 2026, 108 adults with alcohol use disorder and obesity had 26 weeks of once-weekly 2.4 mg semaglutide plus CBT, against placebo plus CBT. Heavy drinking days fell significantly, an estimated treatment difference of 13.7 percentage points.
Independent reviewers set out the caveats: a single centre, motivated self-selected participants, 10 CBT sessions for everyone that many services cannot match, no post-treatment follow-up, and a population limited to people with obesity.
No GLP-1 receptor agonist is licensed in the UK for alcohol use disorder, and reviewers call for larger and longer trials before practice changes.
Frequently asked questions
How many units of alcohol a week is safe in the UK?
The UK Chief Medical Officers advise no more than 14 units a week on a regular basis, and that applies equally to men and women. The guidance also says to spread those units over three or more days. It sets a low risk level, because risk rises the more you drink regularly.
Is it better to cut down gradually or stop completely?
For most people who want to reduce their drinking, gradual swapping and downsizing works better than stopping outright in one step. Small habitual drinks are usually what builds a weekly unit total. If you drink heavily every day, speak to your GP first, because acute alcohol withdrawal is managed medically.
What medication is available in the UK for drinking too much?
Four medicines sit within UK guidance: acamprosate, oral naltrexone, disulfiram and nalmefene. Acamprosate and naltrexone are usually taken for up to six months alongside a psychological intervention. Disulfiram is for people aiming at abstinence. Nalmefene is taken as needed to reduce consumption. All are prescribed by a clinician after an assessment.
Does semaglutide help you drink less?
There is early trial evidence, and no GLP-1 receptor agonist is licensed in the UK for alcohol use disorder. A 2026 Lancet trial in 108 adults with alcohol use disorder and obesity found a significant reduction in heavy drinking days, but it was a single centre study with no follow-up.
About Panthera
Panthera Biopartners is the UK’s largest site management organisation for commercial clinical trials, with seven clinics in Glasgow, Enfield, Keele, Preston, Rochdale, Sheffield and York. It runs studies on behalf of sponsors and contract research organisations, and does not conduct first-in-human studies. Panthera lists its alcohol consumption clinical trials online. Anyone considering a study has time to read a Participant Information Sheet and ask questions before consenting, participation is voluntary, and a participant may withdraw at any time.
Disclaimer
Not medical advice. This article is general information about alcohol, UK guidance and current research. Speak to your GP about your own drinking and any medicine mentioned here.
Conflicts and affiliations. Panthera Biopartners runs clinical trials, including studies relating to alcohol consumption. Whether a trial is suitable for you is a decision for you, your clinician and the study team, after you have read the Participant Information Sheet.